LBLuigi Bartalena

Luigi Bartalena

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Luigi Bartalena has a total of 135 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Pre-operative evaluation of obese patients admitted for bariatric surgery: observations suggesting the introduction of a detailed screening for thyroid diseases

    by Daniela Gallo, Silvia Ippolito, Jessica Sabatino, Giovanni Veronesi, Francesco Frattini, Eugenia Dozio, Eugenia Trotti, Valeria Cortinovis, Federico Giussani, Adriana Lai, et al.

    Background: So far, guidelines for bariatric surgery do no recommend the universal screening for thyroid diseases, except the TSH measurement in selected patients. However, a possible interplay between obesity (possibly complicated by obesity-related comorbidities) and thyroid diseases has been postulated. Objective: Aim of the study was to investigate the prevalence of thyroid diseases in a cohort of obese patients, evaluated for bariatric surgery. Methods in the study period 2014–2017, 88 patients (72 women and 16 men, mean age 43±11 years), with second or third class obesity, were consecutively screened at the Outpatients Clinic for the study of Obesity, University of Insubria. All patients had preliminary psychosocial tests, nutritional, surgical and endocrinological evaluations. Beyond the pre-operative analysis recommended by the international and national guidelines, serum TSH, TPOAb and TgAb levels and neck ultrasound were assessed. When clinically appropriate, further tests, such as calcitonin determination and thyroid fine needle aspiration were performed. Thyroid diseases were classified as thyroid autoimmune disease, nodular disease, goiter, primitive hypothyroidism or hyperthyroidism. Results: 45/88 patients were eligible for bariatric surgery. Data were collected on the whole study-population (88 patients). Interestingly, patients that fulfilled the diagnosis of metabolic syndrome (34%) had higher incidence of thyroid diseases (P=0.002). Forty patients out of eighty-eight patients (45.5%) had thyroid diseases (17 new cases, 42.5%). Among patients with known thyroid diseases, 23% were treated with levothyroxine (mean dose 0.86 mcg/Kg body weight/day). Mean thyroid volume was 16.7±6.5 ml in women and 17.5±2.9 ml in men; mean TSH level was 2.1±1.2 μU/ml. According to the results of thyroid ultrasound, 78% of patients had hypoecogenic pattern, 24% (21/88) had goiter (52% previously undiagnosed), while 35% had nodular disease (31/88, new diagnosis in 55% of cases). Fifteen patients had autoimmune thyroiditis (17%), of which 40% was newly discovered. Two patients had differentiated thyroid carcinoma (one new case). Conclusion: Prevalence of thyroid diseases, especially goiter (24% vs 10% in the general population), was higher in the study-population than that observed in normal-weight patients. Interestingly a high proportion of thyroid diseases were undiagnosed. Moreover the incidence of thyroid diseases was higher in patients with metabolic syndrome. Consistent evidences from large trials are warranted. According to these preliminary data, we suggest the introduction of detailed thyroid screening in pre-operative evaluation of obese patients admitted for bariatric surgery.

  • Demographic and baseline characteristics of an obese population admitted for bariatric surgery in a secondary care centre

    by Daniela Gallo, Silvia Ippolito, Giovanni Veronesi, Eugenia Dozio, Francesco Frattini, Eugenia Trotti, Adriana Lai, Lorenza Sassi, Jessica Sabatino, Elvira Masiello, et al.

    Obesity has become one of the greatest public health concerns and is known to be a major risk factor for cardiac, respiratory and metabolic diseases. Bariatric surgery is the most effective treatment for morbid obesity. According with guidelines, surgery is indicated for treatment of patients with BMI greater than 40 kg/m2 or above 35 kg/m2, with at least one obesity-related comorbid condition, such as as type 2 diabetes, hypertension, dyslipidemia, sleep apnea, osteoarthritis. Nowadays, sleeve gastrectomy is one of the most common techniques, able to cure metabolic disorders, allowing a shorter convalescence and fewer complications. We herein describe the baseline characteristics of 38 adults (35 women, mean age 41±13 years), suitable for surgery. Patients were referred by Surgeons or other Specialists such as Cardiologists, Pulmonologists, Nephrologists or Orthopedicians. Three patients were admitted for the conversion of laparoscopic adjustable gastric banding, to achieve additional weight loss. In keeping with guidelines, BMI was 43.3±6 Kg/m2 (71% ≥40 kg/m2, 23.5% 35–39.9 kg/m2, 5.3% 2), with a visceral pattern of obesity (waist circumference 123±11 cm). Half of the patients suffered from metabolic syndrome, defined according to IDF/AHA/NHLB harmonized definition. Actually, 29% had diabetes, 37% hypertension and 53% dyslipidemia. Among the others, arthropathy was the most frequent comorbidity (21%), followed by respiratory diseases (chronic obstructive or restrictive pulmonary disease, 19%), chronic venous insufficiency (11%) or heart diseases (5.3%). We observed gastric diseases in almost half of the population (44%), and, as expected, 24% had hiatal hernia. Beyond these, 71% of patients emerged to have thyroid disease, with a high prevalence of non-toxic goiter and Hashimoto’s thyroiditis. During the screening, papillary thyroid cancer was disclosed in two patients (5.3%). According to the literature, these data underscore the high prevalence of obesity-related morbilities and the need for an effective and urgent treatment.

  • Nodule size and fine-needle aspiration biopsy: diagnostic challenges for thyroid malignancy

    by Stefano Rausei, Gianlorenzo Dionigi, Francesco Frattini, Patrizia Castano, Andrea Leotta, Francesca Rovera, Luigi Boni, Luigi Bartalena, Renzo Dionigi


    • 1 March 2010
      • p. 210-6

    Novel treatment modalities for Graves' orbitopathy.

    by Luigi Bartalena, Adriana Lai, Lorenza Sassi, Valentina Lombardi, Ilaria Dalle Mule, Myriam Gandolfo, Luigi Liparulo, Claudio Azzolini, Eliana Piantanida, Maria Laura Tanda

    Non-surgical treatments for moderate to severe and active Graves' orbitopathy (systemic glucocorticoids with or without orbital radiotherapy) have limited effects on the underlying autoimmune process causing the disease. Although the clinical responses to treatment are often good, at least one third of patients with Graves' orbitopathy are eventually dissatisfied with the treatment outcome. Progress in our understanding of the autoimmune basis of Graves' orbitopathy (although still incomplete) made it possible, similar to other autoimmune disorders, to envision the use of novel immunomodulating drugs. Among the currently available biologic agents, the CD20+ B cell-depleting agent, rituximab, and tumor necrosis factor-alpha inhibitors are presently the drugs that have the best chance of being employed in the future for the treatment of Graves' orbitopathy. However, randomized, controlled clinical trials to support their use are warranted.


    • 1 March 2010
      • p. 173

    Grave's ophthalmopathy (GO), are the extrathyroidal manifestations of Grave's disease. Foreword.

    by Gerasimos E Krassas, Luigi Bartalena, Carlos Benbassat

  • Thyroid Hormone Treatment for Differentiated Thyroid Carcinoma: What Drug, How Long, What Dose?

    by Eliana Piantanida, Emanuele Compri, Myriam Gandolfo, Lorenza Sassi, Gianlorenzo Dionigi, Adriana Lai, Maria Laura Tanda, Luigi Bartalena

    Treatment with thyroid hormone is needed in patients with differentiated thyroid carcinoma (DTC) after the initial treatment (thyroidectomy followed, in most cases, by radioiodine remnant ablation) for two reasons: a) Correction of hypothyroidism in an athyreotic patient (replacement therapy); b) Blockade of thyrotropin (TSH) secretion in view of the TSH-dependence of DTC (TSH-suppressive therapy). Levothyroxine (L-T4) is the hormone of choice, since combination with levotriiodothyronine does not add any clear advantage with respect to L-T4 monotherapy. While replacement therapy obviously is a lifelong requirement, duration of TSH-suppressive therapy depends on the tumor risk stratification after and the response to the initial treatment. According to recent European and American guidelines, in low-risk DTC LT4 treatment should be carried out at TSH-suppressive doses until there is evidence that the patient is disease-free. In high-risk DTC, TSH suppression should be maintained for several years after such an evidence has been achieved. Afterwards, the patient can be shifted to replacement doses, also to avoid the risks of iatrogenic thyrotoxicosis, especially in the elderly and/or in the presence of cardiovascular disease. The dose of L-T4 must be invidualized; particular attention must be given to the coexistence of pathophysiological conditions or drug treatments that may affect L-T4 absorption or metabolism.

  • Open Access

    Glucocorticoids Are Preferable to Thionamides as First-Line Treatment for Amiodarone-Induced Thyrotoxicosis due to Destructive Thyroiditis: A Matched Retrospective Cohort Study

    by Fausto Bogazzi, Luca Tomisti, Giuseppe Rossi, Enrica Dell'Unto, Pasquale Pepe, Luigi Bartalena, Enio Martino

    Context: Type 2 amiodarone-induced thyrotoxicosis (AIT) is a destructive thyroiditis usually responsive to glucocorticoids; however, recent surveys showed that many expert thyroidologists worldwide use thionamides for type 2 AIT patients. Objective: The objective of the study was to compare the effectiveness of methimazole (MMI) or prednisone (GLU) in type 2 AIT patients who had a short cure time according to a published predictive model. Design: This was a matched retrospective cohort study. Setting: The study was conducted at a university center. Patients: Forty-two untreated type 2 AIT patients with a predicted cure time ≤40 d were divided into two groups (MMI and GLU groups). After matching for the predicted cure time, patients in the GLU group were selected in a 1:1 ratio to patients in the MMI group. Intervention: Patients were treated with GLU or MMI for 40 d. Patients still thyrotoxic after 40 d continued glucocorticoids if in the GLU group or were switched to prednisone (MMI-GLU group) if in the MMI group. Main Outcome Measure: Time and rate of cure (healing) at 40 d were measured. Results: Patients still thyrotoxic after 40 d were 23.8 ± 9.3% in the GLU group and 85.7 ± 7.6% in the MMI group (P = 0.000). The GLU and MMI-GLU groups did not significantly differ in the nonhealing rate at 40 d (P = 0.730). When patients in the MMI group were treated with glucocorticoids, 94.1% patients achieved euthyroidism within 40 d. However, the global median cure time (MMI period + prednisone period) was longer (60 d, 95% confidence interval 53.5–66.5 d) in the MMI-GLU group than the GLU group (21 d, 95% confidence interval 15.1–26.9 d). Conclusions: Glucocorticoids are the first-line treatment in type 2 AIT, whereas thionamides play no role in this destructive thyroiditis. Glucocorticoids are the first-line treatment in type 2 amiodarone-induced thyrotoxicosis while thionamides play no role in this destructive thyroiditis.


  • Plasma total and acylated Ghrelin concentrations in patients with clinical and subclinical thyroid dysfunction.

    by M. L. Tanda, V. Lombardi, M. Genovesi, F. Ultimieri, A. Lai, M. Gandolfo, I. Dalle Mule, L. Grasso, F. Bogazzi, F. Broglio, et al.


  • Diagnosis and management of amiodarone‐induced thyrotoxicosis: similarities and differences between North American and European thyroidologists*

    by Maria Laura Tanda, Eliana Piantanida, Adriana Lai, Luigi Liparulo, Lorenza Sassi, Fausto Bogazzi, Wilmar M. Wiersinga, Lewis E. Braverman, Enio Martino, Luigi Bartalena

    Summary: Objective  To investigate how North American thyroidologists assess and treat amiodarone‐induced thyrotoxicosis (AIT) and to compare the results with those of the same questionnaire‐based survey previously carried out among European thyroidologists.Design  Members of the American Thyroid Association (ATA) with clinical interests were sent by e‐mail a questionnaire on the diagnosis and management of AIT, 115 responses were received from the United States and Canada, representing about one‐third of ATA members with clinical interests.Results  The majority of respondents (91%vs. 68% in Europe, P < 0·05) see < 10 new cases of AIT per year, and AIT seems less frequent than amiodarone‐induced hypothyroidism (AIH) in North America (34% and 66% of amiodarone‐induced thyroid dysfunction, respectively, vs. 75% and 25%, respectively, in Europe, P < 0·001). When AIT is suspected, in North America hormonal assessment is mostly based on serum free T4 (FT4) and TSH measurements, while serum free T3 (FT3) determination is requested less frequently than in Europe; thyroid autoimmunity is included in the initial assessment less than in Europe. Most commonly used additional diagnostic procedures include, as in Europe, thyroid colour‐flow Doppler sonography, and to a lesser extent, thyroid radioactive iodine uptake and scan, but Europeans tend to request multiple tests more than North Americans. Withdrawal of amiodarone is more often considered unnecessary by North American thyroidologists (21%vs. 10% in Europe in type 1 AIT, P < 0·05, 34%vs. 20% in type 2 AIT, P < 0·05). In type 1 AIT thionamides represent the treatment of choice for North Americans as well as for Europeans, but the former use them as monotherapy in 65%vs. 51% of Europeans (P < 0·05) who more often consider potassium perchlorate as an useful addition (31%vs. 15% of North Americans, P < 0·01). Glucocorticoids are the selected treatment for type 2 AIT, alone (62%vs. 46% in Europe, P < 0·05) or in association with thionamides (16%vs. 25% in Europe, P = NS). After restoration of euthyroidism, thyroid ablation in the absence of recurrent thyrotoxicosis is recommended in type 1 AIT less frequently by North Americans. If amiodarone therapy needs to be reinstituted, prophylactic thyroid ablation is advised by 76% in type 1 AIT, while a ‘wait‐and‐see’ strategy is adopted by 61% in type 2 AIT, similar to behaviour of European thyroidologists.Conclusion  Similarities and differences exist between expert North American and European thyroidologists concerning the diagnosis and management of AIT. While differences reflect the frequent uncertainty of the underlying mechanism leading to AIT, similarities may represent the basis to refine the diagnostic criteria and to improve the therapeutic outcomes of this challenging clinical situation.